InterMune, Inc. (ITMN) Announces Clinical Data Presented At AASLD That Support Phase III DIRECT Trial For HCV (Hepatitis C Infection)

InterMune, Inc. (ITMN) Announces Clinical Data Presented At AASLD That Support Phase III DIRECT Trial For HCV
BioSpace - Announces Clinical Data Presented At AASLD That Support Phase III DIRECT Trial For HCV SAN FRANCISCO, Nov infected with hepatitis C virus (HCV) who failed to adequately respond to

MIGENIX Initiates Enrollment in Phase IIb Hepatitis C Clinical Study of Celgosivir
BC Technology - inhibitor and is currently the only oral anti-HCV drug in clinical development that acts through host some evidence of antiviral activity in treatment-naive chronic HCV patients.

InterMune Announces Clinical Data Presented at AASLD That Support Phase III DIRECT Trial for HCV
PR Newswire - SAN FRANCISCO, Nov. patients infected with hepatitis C virus (HCV) who failedto adequately respond to first thatevaluated InterMune products in various HCV patient settings were alsopresented at the

Safety and Efficacy of Pegasys Plus Ribavirin in HCV Patients Intolerant or Nonresponsive to Treatment with Pe
HIV and Hepatitis.com - RBV dose reductions also are associated with decreased SVR. Era of Protease Inhibitors for the Treatment of HCV: An Overview of SCH 503034 SCH 503034 is a new, orally administered HCV protease inhibitor that has shown potent

Healthbeat:Hepatitis C
WHOI - borne infection caused by the hepatitis C virus (HCV). The virus causes an infection of the liver, which cancer (cirrhosis of the liver). HCV is curable if detected and treated